Anzeige
Mehr »
Login
Sonntag, 05.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
Cannabisaktien sollten nun den S&P um 60% outperformen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
30 Leser
Artikel bewerten:
(0)

ISTA Pharmaceuticals Announces Conference Call and Webcast of Third Quarter 2010 Financial Results

IRVINE, Calif., Oct. 15 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. today announced it will release third quarter 2010 financial results after market close on November 2, 2010. In conjunction, the Company will host a conference call at 4:30 p.m. Eastern Time focusing on its commercial progress and pipeline updates, conducting a question and answer session after each set of formal comments.

Date: Tuesday, November 2, 2010 Time: 4:30 p.m. Eastern Time Conference call access: Internet: http://www.istavision.com/ Domestic dial-in: 866-202-1971 International dial-in: 617-213-8842 Passcode: 22888741

To access the 24-hour audio replay, U.S. and Canadian participants may dial 888-286-8010; international participants may dial 617-801-6888. The access code for the replay is 97091207. This conference call also will be webcast live and archived on ISTA's website until December 31, 2010.

About ISTA Pharmaceuticals

ISTA Pharmaceuticals, Inc. is the fourth largest and fastest growing branded prescription eye care business in the United States, with an expanding focus on allergy therapeutics. ISTA currently markets four products, including treatments for ocular inflammation and pain post-cataract surgery, glaucoma and ocular itching associated with allergic conjunctivitis. The Company's development pipeline contains additional candidates in various stages of development to treat dry eye, ocular inflammation and pain and nasal allergies. Headquartered in Irvine, California, the Company generated 2009 revenues of $111 million. For additional information about ISTA Pharmaceuticals, please visit the corporate website at http://www.istavision.com/.

ISTA Pharmaceuticals, Inc.

CONTACT: Investor Relations: Lauren Silvernail, +1-949-788-5302,
lsilvernail@istavision.com, or Jeanie Herbert, +1-949-789-3159,
jherbert@istavision.com, both of ISTA Pharmaceuticals, Inc.; or Justin Jackson
(Media), +1-212-213-0006, jjackson@burnsmc.com, or Juliane Snowden (Investor
Relations), +1-212-213-0006, jsnowden@burnsmc.com, both of Burns McClellan

Web Site: http://www.istavision.com/

Lithium vs. Palladium - Zwei Rohstoff-Chancen traden
In diesem kostenfreien PDF-Report zeigt Experte Carsten Stork interessante Hintergründe zu den beiden Rohstoffen inkl. . Zudem gibt er Ihnen konkrete Produkte zum Nachhandeln an die Hand, inkl. WKNs.
Hier klicken
© 2010 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.